Skip to main content
Premium Trial:

Request an Annual Quote

Following Financial Restructuring, Nabsys Resurfaces With Much of Original Leadership Team

NEW YORK (GenomeWeb) – Six months after closing its doors, Nabsys said today that it has completed a financial restructuring and reassembled much of its original leadership team, including its original CEO.

According to the company, founding CEO Barrett Bready returned last October, just a month after Nabsys reportedly shuttered its facility. Several members of the original technical development team have also come back, including CTO John Oliver, Executive Vice President of Product Development Steve Nurnberg, and Vice President of Software and Informatics Michael Kaiser.

Nabsys, a Providence, Rhode Island-based spinout from Brown University, has been developing a semiconductor-based nanodetector technology for single-molecule DNA mapping, with possible applications in structural variation analysis, genome mapping, and, ultimately, DNA sequencing. Between 2009 and 2013, the company raised $41 million in private equity. Originally, the firm was planning to commercialize a platform in 2014, with de novo assembly of microbial genomes as one of the first applications.

However, following a management shake-up in 2014, when Nabsys brought in former Real Time Genomics CEO Steve Lombardi as CEO and former Ignyta CTO Tony Shuber as CSO, the company switched its focus to cancer applications and human structural variation analysis and was developing a new generation of chips with larger numbers of nanodetectors.

In a statement today, Nabsys said that under the new management, the company "pivoted to a different and ultimately unsuccessful technical approach" in early 2015. Bready has now refocused the company on its core technology.

"The fact that we were able to get the team organized so quickly meant that very little time was lost during this transition period. The past six months have been the most productive in the company's history," Bready said in a statement.

"We are excited to once again be exploring the potential of this technology as a team and anticipate sharing our progress in the near future," Oliver said in the statement.

Nabsys did not provide details about its financial structuring, but according to a local news report last December, Bready purchased the company for $500,000 and assumed $100,000 of its debt.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.